ARCHIVES

NLST Suggests 18.5 Percent Of LDCT-Detected Cancers Could Be Indolent

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

October 3, 2014

Two Phase II Studies of Ibrutinib Deliver High Response Rates

December 27, 2013

FDA, CMS Take Second Look at Drugs Given “Accelerated” Approval for Cancer

March 21, 2003

Abstracts Of Papers From Gynecologic Oncology Conference

October 10, 1975

Children’s Memorial Hospital Receives $3 Million Endowment From Price Trust

May 28, 2010

Immune Systems Don’t Stop, Causing Fatigue For Survivors

May 26, 2006